Hybrid eventIn-person & virtual
June 24–26, 2027Rome, Italy

Talk Details · Neurology 2024

Terminating the terminator: Glioma/ glioblastoma orthomolecular destruction as a new possible therapeutic intervention

Oral · Virtual · Day 3

Abstract

About this talk

Malignant Glioblastoma Multiforme is the most aggressive of the gliomas, a collection of tumors arising from glia or their precursors within the central nervous system. It accounts for 17% of all primary brain tumors which makes GBM the most common malignant brain tumor. Even with the development of new treatments, 88% of the patients died at 4 years and approximately 12 % survive but with severe neurological disabilities. For most patients, the median survival is approximately 15-20 months in protocol-eligible patients with newly diagnosed GBM. GBM grows rapidly near doubling it’s size in 2-3 weeks. These are enough reasons to get the nickname of “Terminator“ by neurosurgeons working on the neuro-oncology field The challenging nature of GBMs is related to their heterogeneous and invasive phenotype, characterized by areas of angiogenic microvascular proliferation, brain invasion and necrosis. Here, we present a case study of three patients, one with Glioma & two with Glioblastoma Multiforme, that showed complete remission after receiving a combination of antioxidant agents.

Speaker

About the speaker

Juan Moreira

Juan Moreira

CNC / Gnosis Neurointegrative Center, United States

View full speaker profile →

Join the Neurology 2027 delegation

Rome · June 24–26, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.